Spheroid culture of LuCaP 136 patient-derived xenograft enables versatile preclinical models of prostate cancer

[1]  E. Crawford,et al.  Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies. , 2015, The Journal of urology.

[2]  Xian Zhang,et al.  Amplification and protein expression of androgen receptor gene in prostate cancer cells: Fluorescence in situ hybridization analysis. , 2015, Oncology letters.

[3]  S. Hilsenbeck,et al.  Expression of ERG protein in prostate cancer: variability and biological correlates. , 2015, Endocrine-related cancer.

[4]  C. Miranti,et al.  The Host Microenvironment Influences Prostate Cancer Invasion, Systemic Spread, Bone Colonization, and Osteoblastic Metastasis , 2014, Front. Oncol..

[5]  C. Drake.  Visceral metastases and prostate cancer treatment: 'die hard,' 'tough neighborhoods,' or 'evil humors'? , 2014, Oncology.

[6]  P. Nelson,et al.  Spheroid culture of LuCaP 147 as an authentic preclinical model of prostate cancer subtype with SPOP mutation and hypermutator phenotype. , 2014, Cancer letters.

[7]  Rikard Larsson,et al.  The role of PI3K/AKT-related PIP5K1α and the discovery of its selective inhibitor for treatment of advanced prostate cancer , 2014, Proceedings of the National Academy of Sciences.

[8]  M. Loda,et al.  Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. , 2014, Cancer discovery.

[9]  David C. Miller,et al.  Prostate Cancer,,Version 2.2014 Clinical Practice Guidelines in Oncology , 2014 .

[10]  Gary Box,et al.  Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib. , 2014, Journal of the National Cancer Institute.

[11]  B. Fuchs,et al.  CXCR4 antibody treatment suppresses metastatic spread to the lung of intratibial human osteosarcoma xenografts in mice , 2014, Clinical & Experimental Metastasis.

[12]  K. Jennbacken,et al.  Osteoblasts stimulate the osteogenic and metastatic progression of castration-resistant prostate cancer in a novel model for in vitro and in vivo studies , 2013, Clinical & Experimental Metastasis.

[13]  R. Vessella,et al.  Establishment and serial passage of cell cultures derived from LuCaP xenografts , 2013, The Prostate.

[14]  J. Isaacs,et al.  Of mice and men‐warning: Intact versus castrated adult male mice as xenograft hosts are equivalent to hypogonadal versus abiraterone treated aging human males, respectively , 2013, The Prostate.

[15]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[16]  R. Vessella,et al.  Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases , 2013, The Journal of pathology.

[17]  R. Vessella,et al.  Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases , 2013, The Prostate.

[18]  Elisabeth Heath,et al.  Cediranib inhibits both the intraosseous growth of PDGF D‐Positive prostate cancer cells and the associated bone reaction , 2012, The Prostate.

[19]  Kevin W Eliceiri,et al.  NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.

[20]  A. Sivachenko,et al.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.

[21]  R. Grobholz,et al.  Experimental orthotopic prostate tumor in nude mice: techniques for local cell inoculation and three-dimensional ultrasound monitoring. , 2012, Urologic oncology.

[22]  Andrew E. Jaffe,et al.  Bioinformatics Applications Note Gene Expression the Sva Package for Removing Batch Effects and Other Unwanted Variation in High-throughput Experiments , 2022 .

[23]  Lee T. Sam,et al.  Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study , 2011, Science Translational Medicine.

[24]  Stephen J. Salipante,et al.  Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers , 2011, Proceedings of the National Academy of Sciences.

[25]  T. Guise,et al.  Cancer to bone: a fatal attraction , 2011, Nature Reviews Cancer.

[26]  G. Mundy,et al.  Advances in osteoclast biology: old findings and new insights from mouse models , 2011, Nature Reviews Rheumatology.

[27]  Lillian L. Siu,et al.  Preclinical development of molecular-targeted agents for cancer , 2011, Nature Reviews Clinical Oncology.

[28]  M. Karsdal,et al.  Serum N-Terminal Propeptide of Collagen Type I is Associated with the Number of Bone Metastases in Breast and Prostate Cancer and Correlates to Other Bone Related Markers , 2011, Biomarkers in cancer.

[29]  R. Vessella,et al.  Inhibition of angiopoietin‐2 in LuCaP 23.1 prostate cancer tumors decreases tumor growth and viability , 2010, The Prostate.

[30]  R. de Wit,et al.  Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer , 2008, British Journal of Cancer.

[31]  E. Vazquez,et al.  Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. , 2008, The Journal of clinical investigation.

[32]  A. Bjartell,et al.  FGF‐8 is involved in bone metastasis of prostate cancer , 2008, International journal of cancer.

[33]  V. A. Villar,et al.  Dopamine 5 receptor mediates Ang II type 1 receptor degradation via a ubiquitin-proteasome pathway in mice and human cells. , 2008, The Journal of clinical investigation.

[34]  R. Vessella,et al.  Prostate cancer-associated membrane type 1-matrix metalloproteinase: a pivotal role in bone response and intraosseous tumor growth. , 2007, The American journal of pathology.

[35]  E. Sausville,et al.  Contributions of human tumor xenografts to anticancer drug development. , 2006, Cancer research.

[36]  Ximing J. Yang,et al.  Application of alpha-methylacyl coenzyme A racemase immunohistochemistry in the diagnosis of prostate cancer: a review. , 2006, Analytical and quantitative cytology and histology.

[37]  R. Vessella,et al.  Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment , 2006, BMC Cancer.

[38]  M. Sadar,et al.  Cell lines used in prostate cancer research: a compendium of old and new lines--part 1. , 2005, The Journal of urology.

[39]  Gordon K. Smyth,et al.  limmaGUI: A graphical user interface for linear modeling of microarray data , 2004, Bioinform..

[40]  C. U. Uyl‐de Groot,et al.  Costs of prostate cancer, metastatic to the bone, in the Netherlands. , 2003, European urology.

[41]  C. Contag,et al.  Animal models of bone metastasis , 2003, Cancer.

[42]  C. Wood,et al.  Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. , 2001, Cancer research.

[43]  D. Grignon,et al.  Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. , 1999, Cancer research.

[44]  R. Vessella,et al.  Mechanisms, Hypotheses and Questions Regarding Prostate Cancer Micrometastases to Bone , 1998, Cancer and Metastasis Reviews.

[45]  E. A. Wright,et al.  Effect of castration and testosterone propionate on mouse vibrissae , 1983, The British journal of dermatology.

[46]  A. D'Amico,et al.  Prostate cancer, version 2.2014. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.